{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:24:22Z","timestamp":1790267062535,"version":"4.1.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"am","delay-in-days":392,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100009160","name":"Universite de Toulouse 3","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009160","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.therap.2023.11.003","type":"journal-article","created":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T00:32:31Z","timestamp":1700267551000},"page":"189-197","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Drug-induced tumoral disease: A global pharmacovigilance database analysis"],"prefix":"10.1016","volume":"79","author":[{"given":"Yoann","family":"Zelmat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Despas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2023.11.003_bib0270","unstructured":"World Health Organization. Cancer. 2022. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cancer. [Accessed 16 November 2023]."},{"key":"10.1016\/j.therap.2023.11.003_bib0275","unstructured":"American Cancer Society. Known and probable human carcinogens. 2023. https:\/\/www.cancer.org\/cancer\/risk-prevention\/understanding-cancer-risk\/known-and-probable-human-carcinogens.html. [Accessed 16 November 2023]."},{"key":"10.1016\/j.therap.2023.11.003_bib0280","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.therap.2020.02.022","article-title":"Uses of pharmacovigilance databases: an overview","volume":"75","author":"Bihan","year":"2020","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2023.11.003_bib0285","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.therap.2019.01.006","article-title":"Case\u2013non-case studies: principle, methods, bias and interpretation","volume":"74","author":"Faillie","year":"2019","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2023.11.003_bib0290","unstructured":"ANSM. Suspension de l\u2019utilisation des m\u00e9dicaments contenant de la pioglitazone (Actos\u00ae, Competact\u00ae) \u2013 Lettre aux professionnels de sant\u00e9 \u2013 Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9 (ANSM). 2011. https:\/\/archive.ansm.sante.fr\/S-informer\/Informations-de-securite-Lettres-aux-professionnels-de-sante\/Suspension-de-l-utilisation-des-medicaments-contenant-de-la-pioglitazone-Actos-R-Competact-R-Lettre-aux-professionnels-de-sante. [Accessed 16 November 2011]."},{"key":"10.1016\/j.therap.2023.11.003_bib0295","series-title":"FDA Requests removal of all ranitidine products (Zantac) from the Market","year":"2020"},{"key":"10.1016\/j.therap.2023.11.003_bib0300","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1053\/j.gastro.2020.12.037","article-title":"Ranitidine use and cancer risk: results from UK biobank","volume":"160","author":"Kantor","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.therap.2023.11.003_bib0305","doi-asserted-by":"crossref","first-page":"102637","DOI":"10.1016\/j.dsx.2022.102637","article-title":"Bladder cancer with pioglitazone: a case-control study","volume":"16","author":"Malhotra","year":"2022","journal-title":"Diabetes Metab Syndr"},{"key":"10.1016\/j.therap.2023.11.003_bib0310","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/ijc.10980","article-title":"Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists","volume":"104","author":"Yoshimura","year":"2003","journal-title":"Int J Cancer"},{"key":"10.1016\/j.therap.2023.11.003_bib0315","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.3390\/cells11152432","article-title":"Peroxisome proliferator-activated receptors and the hallmarks of cancer","volume":"11","author":"Wagner","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.therap.2023.11.003_bib0320","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/sj.neo.7900050","article-title":"Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in human transitional bladder cancer and its role in inducing cell death","volume":"1","author":"Guan","year":"1999","journal-title":"Neoplasia"},{"key":"10.1016\/j.therap.2023.11.003_bib0325","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.3109\/10428194.2012.666545","article-title":"Secondary malignancy after imatinib therapy: eight cases and review of the literature","volume":"53","author":"Duman","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.therap.2023.11.003_bib0330","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3109\/10428194.2013.806805","article-title":"The occurrence of second neoplasms after treatment with tyrosine kinase inhibitors for chronic myeloid leukemia","volume":"55","author":"Togasaki-Yoshimoto","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.therap.2023.11.003_bib0335","first-page":"e35436","article-title":"A rare case of metastatic small cell carcinoma of lung in a follow-up patient of chronic myeloid leukemia on imatinib treatment","volume":"15","author":"Singh","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.therap.2023.11.003_bib0340","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nrd2907","article-title":"Cell cycle kinases as therapeutic targets for cancer","volume":"8","author":"Lapenna","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.therap.2023.11.003_bib0345","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/387450a0","article-title":"DNA repair. A sense-abl response?","volume":"387","author":"Brown","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.therap.2023.11.003_bib0350","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ejca.2021.10.034","article-title":"Ibrutinib-related skin cancer: a pharmacovigilance study from the Food and Drug Administration Adverse Event Reporting System","volume":"160","author":"Sun","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.therap.2023.11.003_bib0355","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.3390\/cancers13102344","article-title":"Photosensitizing medications and skin cancer: a comprehensive review","volume":"13","author":"George","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.therap.2023.11.003_bib0360","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.jaad.2019.12.031","article-title":"Cutaneous eruptions from ibrutinib resembling epidermal growth factor receptor inhibitor\u2013induced dermatologic adverse events","volume":"88","author":"Singer","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.therap.2023.11.003_bib0365","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.3390\/cancers12092535","article-title":"Tamoxifen and endometrial cancer: a janus-headed drug","volume":"12","author":"Emons","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.therap.2023.11.003_bib0370","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1002\/cncr.29332","article-title":"Aromatase inhibitors, tamoxifen, and endometrial cancer in breast cancer survivors","volume":"121","author":"Chlebowski","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.therap.2023.11.003_bib0375","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1248\/bpb.b22-00530","article-title":"Tamoxifen regulates epithelial-mesenchymal transition in endometrial cancer via the CANP10\/NRP1 signaling pathway","volume":"45","author":"Lv","year":"2022","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.therap.2023.11.003_bib0380","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0300-483X(02)00612-1","article-title":"Immunosuppressive drugs and cancer","volume":"185","author":"Vial","year":"2003","journal-title":"Toxicology"},{"key":"10.1016\/j.therap.2023.11.003_bib0385","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.2165\/00003495-200767080-00006","article-title":"Immunosuppressive therapy and malignancy in organ transplant recipients","volume":"67","author":"Gutierrez-Dalmau","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.therap.2023.11.003_bib0390","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S0022-3476(05)82071-2","article-title":"Cutaneous lesions associated with cyclosporine therapy in pediatric renal transplant recipients","volume":"119","author":"Halpert","year":"1991","journal-title":"J Pediatr"},{"key":"10.1016\/j.therap.2023.11.003_bib0395","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.rdc.2020.03.001","article-title":"Autoimmunity, clonal hematopoiesis, and myeloid neoplasms","volume":"46","author":"Bekele","year":"2020","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.therap.2023.11.003_bib0400","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.beha.2019.02.002","article-title":"Myeloid disorders after autoimmune disease","volume":"32","author":"Boddu","year":"2019","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.therap.2023.11.003_bib0405","doi-asserted-by":"crossref","first-page":"e506","DOI":"10.1038\/bcj.2016.114","article-title":"Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial","volume":"6","author":"Jones","year":"2016","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.therap.2023.11.003_bib0410","first-page":"9534","article-title":"Eruptive basal cell carcinoma and lenalidomide: rising awareness among dermatologists","volume":"15","author":"Pagliarello","year":"2022","journal-title":"Dermatol Reports"},{"key":"10.1016\/j.therap.2023.11.003_bib0415","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nrc2628","article-title":"Tumour necrosis factor and cancer","volume":"9","author":"Balkwill","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.therap.2023.11.003_bib0420","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/annrheumdis-2011-201244","article-title":"Adalimumab: long-term safety in 23,458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease","volume":"72","author":"Burmester","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.therap.2023.11.003_bib0425","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1001\/jamadermatol.2020.1300","article-title":"Melanoma risk in patients treated with biologic therapy for common inflammatory diseases: a systematic review and meta-analysis","volume":"156","author":"Esse","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.therap.2023.11.003_bib0430","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.rmed.2012.11.008","article-title":"Long-term safety study of infliximab in moderate-to-severe chronic obstructive pulmonary disease","volume":"107","author":"Rennard","year":"2013","journal-title":"Respir Med"},{"key":"10.1016\/j.therap.2023.11.003_bib0435","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1093\/rheumatology\/keab570","article-title":"Short- and longer-term cancer risks with biologic and targeted synthetic disease-modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice","volume":"61","author":"Huss","year":"2022","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.therap.2023.11.003_bib0440","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/ijd.13129","article-title":"The risk of malignancy or progression of existing malignancy in patients with psoriasis treated with biologics: case report and review of the literature","volume":"55","author":"Patel","year":"2016","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.therap.2023.11.003_bib0445","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1177\/12034754211038509","article-title":"Risk of developing melanoma with systemic agents used to treat psoriasis: a review of the literature","volume":"26","author":"Semaka","year":"2022","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.therap.2023.11.003_bib0450","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/sj.cdd.4401610","article-title":"Carcinogenesis, cancer therapy and chemoprevention","volume":"12","author":"Blagosklonny","year":"2005","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.therap.2023.11.003_bib0455","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/21556660.2022.2073101","article-title":"A review of the risks of long-term consequences associated with components of the CHOP chemotherapy regimen","volume":"11","author":"Watson","year":"2022","journal-title":"J Drug Assess"},{"key":"10.1016\/j.therap.2023.11.003_bib0460","doi-asserted-by":"crossref","first-page":"369","DOI":"10.7326\/M19-3369","article-title":"Adverse effects of low-dose methotrexate: a randomized trial","volume":"172","author":"Solomon","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.therap.2023.11.003_bib0465","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jaad.2022.11.043","article-title":"Risk of melanoma and nonmelanoma skin cancer with immunosuppressants, part II: methotrexate, alkylating agents, biologics, and small molecule inhibitors","volume":"88","author":"Kreher","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.therap.2023.11.003_bib0470","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S2215-0366(21)00241-8","article-title":"Antipsychotic use and risk of breast cancer in women with schizophrenia: a nationwide nested case-control study in Finland","volume":"8","author":"Taipale","year":"2021","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.therap.2023.11.003_bib0475","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S2215-0366(22)00044-X","article-title":"Long-term treatment with clozapine and other antipsychotic drugs and the risk of haematological malignancies in people with schizophrenia: a nationwide case-control and cohort study in Finland","volume":"9","author":"Tiihonen","year":"2022","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.therap.2023.11.003_bib0480","doi-asserted-by":"crossref","first-page":"103680","DOI":"10.1016\/j.msard.2022.103680","article-title":"Incidence of cancer in patients with multiple sclerosis (MS) who were treated with fingolimod: a systematic review and meta-analysis","volume":"59","author":"Askari","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.therap.2023.11.003_bib0485","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/ana.25701","article-title":"Cancer risk for fingolimod, natalizumab, and rituximab in multiple sclerosis patients","volume":"87","author":"Alping","year":"2020","journal-title":"Ann Neurol"},{"key":"10.1016\/j.therap.2023.11.003_bib0490","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus placebo or adalimumab in rheumatoid arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.therap.2023.11.003_bib0495","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1038\/s41375-020-0987-6","article-title":"Second cancer incidence in CLL patients receiving BTK inhibitors","volume":"34","author":"Bond","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.therap.2023.11.003_bib0500","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41408-019-0237-1","article-title":"Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia","volume":"9","author":"Kumar","year":"2019","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.therap.2023.11.003_bib0505","doi-asserted-by":"crossref","first-page":"55","DOI":"10.4174\/astr.2022.102.1.55","article-title":"Hepatocellular carcinoma and cancer-related mortality after kidney transplantation with rituximab treatment","volume":"102","author":"Lee","year":"2022","journal-title":"Ann Surg Treat Res"},{"key":"10.1016\/j.therap.2023.11.003_bib0510","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/978-1-4939-2895-8_14","article-title":"Glucocorticoids and cancer","volume":"872","author":"Pufall","year":"2015","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.therap.2023.11.003_bib0515","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/cpt.2951","article-title":"Interpretation of pharmacovigilance disproportionality analyses","volume":"114","author":"Khouri","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.therap.2023.11.003_bib0520","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1111\/bcp.15269","article-title":"Conceiving, conducting, reporting, interpreting, and publishing disproportionality analyses: a call to action","volume":"88","author":"Raschi","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2023.11.003_bib0525","doi-asserted-by":"crossref","first-page":"668765","DOI":"10.3389\/fphar.2021.668765","article-title":"Leveraging the variability of pharmacovigilance disproportionality analyses to improve signal detection performances","volume":"12","author":"Khouri","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.therap.2023.11.003_bib0530","doi-asserted-by":"crossref","first-page":"116685","DOI":"10.1016\/j.bone.2023.116685","article-title":"Validity, relevance and interpretation of pharmacovigilance disproportionality analyses","volume":"170","author":"Cortes","year":"2023","journal-title":"Bone"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595723001853?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595723001853?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T19:59:03Z","timestamp":1711655943000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595723001853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0040595723001853"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2023.11.003","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug-induced tumoral disease: A global pharmacovigilance database analysis","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2023.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}